Publications de Stephane Kontos

Bicyclic Peptides Conjugated to an Albumin-Binding Tag Diffuse Efficiently into Solid Tumors

Christian Heinis, Sandeep Raghunathan, Stephane Kontos, Alessandro Angelini, Lisa Pollaro, Julia Morales Sanfrutos

Monoclonal antibodies have long in vivo half-lives and reach high concentrations in tumors but cannot access all regions in the tissue, whereas smaller ligands such as peptides distribute better but are limited by low concentrations due to fast renal clear ...

Amer Assoc Cancer Research2015

Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens

Jeffrey Alan Hubbell, Stephane Kontos, Alizée Jéléna Grimm, Xavier Fredy René Quaglia-Thermes, Giacomo Olimpio Diaceri

New approaches based on induction of antigen-specific immunological tolerance are being explored for treatment of autoimmunity and prevention of immunity to protein drugs. Antigens associated with apoptotic debris are known to be processed tolerogenically ...

Nature Publishing Group2015

Engineering antigen-specific immunological tolerance

Jeffrey Alan Hubbell, Stephane Kontos, Alizée Jéléna Grimm

Unwanted immunity develops in response to many protein drugs, in autoimmunity, in allergy, and in transplantation. Approaches to induce immunological tolerance aim to either prevent these responses or reverse them after they have already taken place. We pr ...

Current Biology Ltd2015

Materials and protein engineering approaches for modulating immunity

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Stephane Kontos, Kristen Lorentz, Alizée Jéléna Grimm, Laura Jeanbart, David Scott Wilson, Kym Lorenz Brünggel

Amer Chemical Soc2014

Engineering antigens for in situ erythrocyte binding induces T-cell deletion

Jeffrey Alan Hubbell, Stephane Kontos, Iraklis Kourtis, Karen Dane

Antigens derived from apoptotic cell debris can drive clonal T-cell deletion or anergy, and antigens chemically coupled ex vivo to apoptotic cell surfaces have been shown correspondingly to induce tolerance on infusion. Reasoning that a large number of ery ...

Natl Acad Sciences2013

Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Stephane Kontos, Iraklis Kourtis, Sachiko Hirosue

Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biol ...

Public Library of Science2013

Erythrocyte-binding therapeutics

Jeffrey Alan Hubbell, Stephane Kontos, Karen Dane

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared a ...

2013

Long-term maintenance of mouse embryonic stem cell pluripotency by manipulating integrin signaling within 3D scaffolds without active Stat3

Jeffrey Alan Hubbell, Stephane Kontos, Seung Tae Lee, Jungim Yun

We engineered an acellular biomimetic microenvironment to regulate stem cell fate and applied it to maintain mouse embryonic stem (ES) cell self-renewal. In the 3D environment formed using hydrogel scaffolds in which specific integrin ligation was provided ...

Elsevier Sci Ltd2012

Drug development: longer-lived proteins

Jeffrey Alan Hubbell, Stephane Kontos

Protein therapeutics represent a powerful class of clinically approved drugs for the prevention and treatment of various diseases. Once administered, the biological fate of protein therapeutics is governed by the body's various complex biochemical and biop ...

Royal Society of Chemistry2012

Engineering Erythrocyte Affinity for Improved Pharmacokinetics and Immune Tolerogenesis

Stephane Kontos

The clinical success of recombinant protein therapeutics in the treatment of disease is a hallmark of modern medical research, yet there remain numerous unaddressed issues regarding their delivery and immunogenicity. Regardless of in vivo efficacy, the bio ...

EPFL2011

Engineered aprotinin for improved stability of fibrin biomaterials

Jeffrey Alan Hubbell, Peter Frey, Stephane Kontos, Kristen Lorentz

Fibrin has been long used clinically for hemostasis and sealing, yet extension of use in other applications has been limited due to its relatively rapid resorption in vivo, even with addition of aprotinin or other protease inhibitors. We report an engineer ...

2011

Engineering integrin signaling for promoting embryonic stem cell self-renewal in a precisely defined niche

Jeffrey Alan Hubbell, Jong Eun Ihm, Yun Suk Jo, Mayumi Mochizuki Martino, Stephane Kontos, Seung Tae Lee, Jungim Yun

We present development and use of a 3D synthetic extracellular matrix (ECM) analog with integrin- specific adhesion ligands to characterize the microenvironmental influences in embryonic stem cell (ESC) self-renewal. Transcriptional analysis of 24 integrin ...

Elsevier2010

Improving Protein Pharmacokinetics by Engineering Erythrocyte Affinity

Jeffrey Alan Hubbell, Stephane Kontos

Poor pharmacokinetic profiles are often the underlying reason for the failure of novel protein drugs to reach clinical translation. Current passive half-life improvement methods focus on increasing the apparent hydrodynamic radius of the drug. We sought to ...

American Chemical Society2010